Lessons From LEADER – All-round Leadership
Open Access
- 1 January 2016
- journal article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 12 (2), 76-78
- https://doi.org/10.17925/ee.2016.12.02.76
Abstract
The large multinational, randomised, double-blind LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation) trial recently reported the cardiovascular (CV) benefits achieved with liraglutide therapy in type 2 diabetes mellitus (T2DM). This editorial analyses the primary and secondary CV outcomes (CVO) results of the LEADER trial, and discusses the impact these will have on clinical practice of diabetes in specific, and medicine in general. It delves into the evolution of clinical and biochemical outcomes used in diabetes, and discusses the role of liraglutide in shaping future outcomes. The editorial describes the potential role of liraglutide in primary, secondary and tertiary prevention of CV disease (CVD), and suggests exaptation of this molecule for use in cardiology, nephrology and neurology.Keywords
This publication has 9 references indexed in Scilit:
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Diabetologia, 2016
- Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effectIndian Journal of Endocrinology and Metabolism, 2016
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeThe New England Journal of Medicine, 2015
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- One Small Step for Empagliflozin, One Giant Leap for DiabetologyDiabetes Therapy, 2015
- Glucagonlike Peptide 1–Based Drugs and Pancreatitis: Clarity at Last, but What About Pancreatic Cancer?JAMA Internal Medicine, 2013
- The exaptation of endocrine pharmacologyIndian Journal of Endocrinology and Metabolism, 2012
- BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of DermatologistsRheumatology, 2006
- Gallstones in patients with morbid obesity. Relationship to body weight, weight loss and gallbladder bile cholesterol solubility.1993